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Introduction
The diagnosis of mesothelioma is a challenging one. There is no single 
hallmark that is pathognomonic for mesothelioma. Consequently, the 
diagnosis is based upon a constellation of ﬁndings, which include the 
gross distribution of tumor, the histological appearance, and the results 
of adjunctive studies. The diagnosis is further complicated by the wide 
variety of histological appearances that mesotheliomas may assume and 
the large number of entities that can simulate this appearance. There-
fore, a diagnosis of mesothelioma should only be made after cautious 
consideration of the available information.
Numerous immunohistochemical markers have been evaluated for their 
usefulness in diagnosing mesothelioma. Panels have been devised from 
various combinations of these proposed markers, which typically in-
clude both positive markers (i.e., markers that are typically positive for 
mesothelioma and negative for most other tumors with which it may be 
confused) and negative markers.1 Since new markers are constantly be-
ing evaluated and reported upon in the medical literature, the diagnosis 
of mesothelioma appears to be a moving target. The problem is further 
compounded in that pathologists pick a favorite set of markers and use 
them in all situations in which the diagnosis of mesothelioma might be 
considered.
This presentation will attempt to simplify the problem by considering 
the situations in which mesothelioma should be included in the dif-
ferential diagnosis, and then suggesting a diagnostic approach for each 
of these situations. These include cellular epithelial lesions involving a 
serosal surface, cellular spindle cell lesions, paucicellular collagenous 
lesions, and mixed or biphasic lesions.
Cellular epithelial lesions
This category can be further divided into cellular lesions that appear to 
be mesothelial but it may be difﬁcult to tell whether they are benign or 
malignant, and cellular lesions that are clearly malignant but it is not 
clear whether they are mesothelial or some other epithelioid malignancy. 
In the former situation, mesothelial cells may look quite bland whether 
they are reactive or malignant, so cytologic features may be of little 
assistance in arriving at the correct diagnosis. In this circumstance, 
demonstration of invasiveness is the most useful single criterion for 
malignancy. Broad-spectrum keratin stains are particularly helpful in 
the search for subtle evidence of invasion, such as the demonstration of 
keratin positive epithelial cells invading into adipose tissue. The author 
uses for this purpose a cocktail that includes AE1/AE3, Cam5.2, and 
MNF.116. One must be careful not to be misled by tangential cuts or 
entrapped reactive mesothelium that can be misinterpreted as invasion. 2
When one is clearly dealing with an epithelial malignancy involving 
a serosal surface, then an immunohistochemical panel to distinguish 
mesothelial cells from other types of epithelial malignancy is appro-
priate. In this circumstance, it is important to be aware of the gross 
distribution of the tumor.3, 4 Mesotheliomas characteristically present 
as a unilateral pleural effusion, a pleural-based mass, an encompassing 
rind of tumor, or as multiple pleural nodules. This information may be 
obtained from imaging studies or from observations of the surgeon at 
time of biopsy. The most common differential is between mesothelioma 
and adenocarcinoma, with pulmonary adenocarcinoma high on the 
list for pleural lesions. For this purpose, the author uses four positive 
mesothelial markers: calretinin (nuclear and cytoplasmic staining), 
cytokeratins 5/6 (cytoplasmic staining), WT-1 (nuclear staining), and 
D2-40 (membrane staining). In addition, two negative markers are 
employed: carcinoembryonic antigen (CEA) and TTF-1.5 Both of these 
markers have a high sensitivity for pulmonary adenocarcinomas, and 
with respect to mesothelioma, the speciﬁcity of TTF-1 is 100%. 
Pulmonary adenocarcinomas are much lower on the differential 
diagnosis for peritoneal lesions, so a different set of markers is more 
appropriate. Many carcinomas involving the peritoneal cavity are CEA 
negative, and some are cytokeratins 5/6 positive. Furthermore, serous 
papillary carcinomas of the ovary or peritoneum frequently stain posi-
tive for calretinin and WT-1. For peritoneal tumors in women, ER and 
PR staining may be added to the list of negative markers (but frequent-
ly positive in serous papillary tumors). Furthermore, we use BerEP4 
and B72.3 as negative markers in place of CEA and TTF-1. In addition, 
PASD is a useful histochemical stain to look for the presence of neutral 
mucin droplets in the cytoplasm of tumor cells. For peritoneal tumors 
in men, we use calretinin, cytokeratins 5/6, WT-1 and D2-40 as positive 
mesothelial markers and BerEP4 and B72.3 as negative markers.
It is not uncommon for mesothelioma to appear as sheets or nests of tu-
mor cells in a desmoplastic stroma. In this setting, melanoma, large cell 
anaplastic lymphoma, and epithelioid hemangioendothelioma should be 
included in the differential diagnosis. We use broad-spectrum keratin 
immunostaining in this circumstance, since mesotheliomas will stain 
strongly and diffusely positive for cytokeratins.4 A negative staining 
result favors one of the alternative diagnoses listed above and should 
lead to an appropriate battery of immunostains to narrow the differen-
tial diagnosis (e.g., S-100 for melanoma, CD45, CD3, CD20 and CD30 
for lymphoma, and CD31 for epithelioid hemangioendothelioma).
Cellular spindle cell lesions
Cellular spindle cell lesions involving a serosal surface typically invoke 
a differential diagnosis of mesothelioma versus sarcoma, sarcomatoid 
carcinoma, or localized ﬁbrous tumor. Keratin staining is useful for 
distinguishing sarcomatoid mesothelioma from other sarcomas, most 
of which are keratin negative. Exceptions include monophasic synovial 
sarcoma, epithelioid sarcoma, and a few cases of leiomyosarcoma. One 
must be careful not to over interpret keratin positive reactive spindle 
cells at the periphery of a lesion. Using broad-spectrum cytokeratin 
immunostaining, we ﬁnd that more than 95% of sarcomatoid mesothelio-
mas stain for cytokeratins. However, the percentage of cells staining var-
ies from case to case, and there may be variability of staining in different 
areas of the same tumor. Although rather uncommon, keratin negative 
sarcomatoid mesotheliomas do occur. Some of these are due to poor ﬁxa-
tion, in which case vimentin staining will also be negative. Other cases 
may be related to sampling issues. Localized ﬁbrous tumors stain posi-
tive for CD34 and bcl-2 but negative for keratins. Monophasic synovial 
sarcomas stain positive for EMA and display the characteristic SYT/SSX 
fusion transcript by FISH or RT-PCR.6 Clinical history and imaging 
studies may also be useful in sorting out these various possibilities.
Sarcomatoid carcinomas present a more difﬁcult differential diagnostic 
issue.4 These tumors are typically strongly positive for cytokeratins, 
but since they are poorly differentiated, are typically negative for most 
or all carcinoma markers. Similarly, sarcomatoid mesotheliomas are 
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS214
typically negative for most or all mesothelioma markers. The most 
useful differential diagnostic feature is the gross distribution of tumor 
as determined by radiographic studies. The ﬁnding of a mass lesion 
in the lung with extension to the pleura or chest wall should be a “red 
ﬂag” for the surgical pathologist contemplating a diagnosis of sarcoma-
toid mesothelioma. This is especially true for an apical lesion, where 
constraints dictated by the anatomy make the likelihood for pleural 
invasion by a sarcomatoid carcinoma quite high.
Paucicellular collagenous lesions
Fibrotic lesions involving the pleura invoke the differential diagnosis of 
ﬁbrous pleurisy versus desmoplastic mesothelioma. Fibrous pleurisy is 
typically a rather uniform process lacking nodularity. Fibrous pleurisy 
tends to show zonation, with the most cellular aspects of the lesion 
located near the pleural surface. In addition, one may observe capillar-
ies perpendicular to the surface traversing the thickness of the pleural 
lesion. Mitotic activity is of little beneﬁt in the differential diagnosis. 
Furthermore, the ﬁnding of keratin positive spindle cells does not help, 
since both ﬁbrous pleurisy and desmoplastic mesothelioma may display 
this feature.2
A diagnosis of desmoplastic malignant mesothelioma can be made 
when a ﬁbrous pleural lesion demonstrates one or more of the fol-
lowing characteristics: 1) frankly sarcomatoid areas, 2) foci of bland 
necrosis, 3) invasion of lung or chest wall, and 4) distant metastases.7 
Invasion may be more easily demonstrated by means of keratin im-
munostaining. The ﬁnding of keratin positive spindle cells insinuating 
between chest wall adipocytes is a particularly useful feature. Expansile 
pleural nodules are also a useful ﬁnding. Extensive sampling may be 
necessary to demonstrate the diagnostic features of malignancy.
Mixed or biphasic lesions
Although a pleural-based lesion with a biphasic histological pattern 
usually suggests a diagnosis of mesothelioma, other diagnostic pos-
sibilities must also be entertained.8 These include spindle cell carcino-
mas, carcinosarcomas, biphasic synovial sarcomas, and rare cases of 
epithelioid hemangioendothelioma. Biphasic mesotheliomas tend to be 
less differentiated than epithelial mesotheliomas, so staining for some 
mesothelial markers may be lost in the epithelial component. The same 
is true for spindle cell carcinomas and carcinosarcomas, which may fail 
to stain for the usual carcinoma markers. For biphasic pleural tumors, 
we use as positive markers broad-spectrum cytokeratins, calretinin, 
cytokeratins 5/6, WT-1 and D2-40, and as negative markers, CEA and 
TTF-1. The panel for biphasic peritoneal tumors is the same, except 
that we substitute BerEP4 and B72.3 for CEA and TTF-1.5 It should 
be noted that the epithelial component of biphasic synovial sarcoma is 
often positive for calretinin. Distinguishing features include positive 
staining for BerEP4 and negative staining for WT-1. In addition, bipha-
sic synovial sarcomas may stain positive with PASD and demonstrate 
the characteristic fusion transcript by RT-PCR or FISH.
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Surgery for mesothelioma is feasible now at more centers and has 
a lower morbidity and mortality than previously reported. Surgery, 
however, is only part of the treatment package for the disease, and can 
be combined with preoperative, intraoperative, and postoperative thera-
pies. The following is an overview of this concept. 
Staging and operative therapy
Patients are candidates for surgical resection in mesothelioma if a cyto-
reductive procedure can be performed that does not leave gross disease 
at its completion, or, in other words, leaves only microscopic residual 
disease. When enlarged mediastinal lymph nodes are detected by CT or 
PET scan, a mediastinoscopy should be performed. 
Which Operation?
The role of surgery in mesothelioma, as well as what type of surgery 
remains extraordinarily controversial since there is a lack of ran-
domized controlled clinical trials making it impossible to determine 
whether the use of extrapleural pneumonectomy (EPP) or pleurectomy 
(PL) improves survival or effectively palliates the symptoms of the 
disease. There is no doubt that EPP is a more extensive dissection 
and may serve to remove more bulk disease than a PL, chieﬂy in the 
diaphragmatic and visceral pleural surfaces. Some surgeons, however, 
include diaphragmatic resection and pericardial resection with their 
PLs to accomplish removal of “all gross disease.” Recent data from 
Flores and Pass in a series of more than 600 patients having PL or EPP 
for pleural mesothelioma revealed that PL may be just as efﬁcacious as 
EPP for early stage mesothelioma.
Lymph node status has emerged as one of the most important prognos-
tic indicators for patients having EPP. Retrospective data from selected 
small series suggest that for patients with nodal positivity, PL had a 
median survival of 16 months while EPP was 15 months. 
Due to its magnitude, EPP has signiﬁcantly greater morbidity than PL. 
The major complication rate ranges from 20% to 40%, and arrhyth-
mia requiring medical management is the most common complica-
tion, however, Rusch reported a perioperative mortality of 6% to 8% 
after EPP, and Sugarbaker et al. reported a benchmark perioperative 
mortality of 3.4%. Mortalities were due to myocardial infarction and 
presumed pulmonary emboli. 
EPP is associated with distant sites of recurrence compared to locore-
gional sites of recurrence in patients having biopsy only or pleurec-
